We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Microtest will Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine for Expected Clinical Trial

News   Feb 01, 2012

 
Microtest will Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine for Expected Clinical Trial
 
 
 

RELATED ARTICLES

Breakthrough in Battle To Curb Dengue

News

Scientists have engineered the first breed of genetically modified mosquitoes resistant to spreading all four types of the dengue virus.

READ MORE

A Biomaterial-based Vaccine for Blood Cancer

News

An injectable, biomaterial-based vaccine, when combined with standard chemotherapy, resulted in the complete and lasting recovery from, and immunity against, the deadly blood cancer acute myeloid leukemia (AML) in mice.

READ MORE

Gene Therapy for Life-limiting Blood Disorder Becomes Commercially Available

News

bluebird bio Inc. have announced that their gene therapy for the blood disorder transfusion-dependent β-thalassemia (TDT) is commercially available for the first time.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE